139 related articles for article (PubMed ID: 35721759)
1. Potential Impact of Body Mass Index on the Clinical Outcome of Papillary Thyroid Cancer After High-Dose Radioactive Iodine Therapy.
Cao J; Zhu X; Sun Y; Li X; Yun C; Zhang W
Front Endocrinol (Lausanne); 2022; 13():870530. PubMed ID: 35721759
[TBL] [Abstract][Full Text] [Related]
2. Potential Impact of BMI on the Aggressiveness of Presentation and Clinical Outcome of Differentiated Thyroid Cancer.
Matrone A; Ceccarini G; Beghini M; Ferrari F; Gambale C; D'Aqui M; Piaggi P; Torregrossa L; Molinaro E; Basolo F; Vitti P; Santini F; Elisei R
J Clin Endocrinol Metab; 2020 Apr; 105(4):. PubMed ID: 31875910
[TBL] [Abstract][Full Text] [Related]
3. The incidence of papillary thyroid carcinoma and outcomes in operative patients according to their body mass indices.
Trésallet C; Seman M; Tissier F; Buffet C; Lupinacci RM; Vuarnesson H; Leenhardt L; Menegaux F
Surgery; 2014 Nov; 156(5):1145-52. PubMed ID: 24878452
[TBL] [Abstract][Full Text] [Related]
4. Association of Body Mass Index With Clinicopathological Features of Papillary Thyroid Carcinoma: A Retrospective Study.
Dong Z; Liu W; Su F; Cheng R
Endocr Pract; 2023 Feb; 29(2):83-88. PubMed ID: 36481471
[TBL] [Abstract][Full Text] [Related]
5. Influence of Body Mass Index on the Clinicopathologic Features of Papillary Thyroid Carcinoma.
Feng JW; Yang XH; Wu BQ; Sun DL; Jiang Y; Qu Z
Ann Otol Rhinol Laryngol; 2019 Jul; 128(7):625-632. PubMed ID: 30841713
[TBL] [Abstract][Full Text] [Related]
6. Potential impact of obesity on the aggressiveness of low- to intermediate-risk papillary thyroid carcinoma: results from a MASTER cohort study.
Kim M; Kang YE; Park YJ; Koo BS; Ku EJ; Choi JY; Lee EK; Kim BH
Endocrine; 2023 Oct; 82(1):134-142. PubMed ID: 37516686
[TBL] [Abstract][Full Text] [Related]
7. Is surgical resection without radioactive iodine treatment a safe alternative treatment for T1-2N1bM0 papillary thyroid carcinoma?
Fujiwara T; Yoshizawa A; Mizuta M; Tamaki H
Auris Nasus Larynx; 2021 Feb; 48(1):148-153. PubMed ID: 32718811
[TBL] [Abstract][Full Text] [Related]
8. Clinical response to radioactive iodine therapy for prophylactic central neck dissection is not superior to total thyroidectomy alone in cN0 patients with papillary thyroid cancer.
Lin B; Qiang W; Wenqi Z; Tianyu Y; Lina Z; Bin J
Nucl Med Commun; 2017 Dec; 38(12):1036-1040. PubMed ID: 28953211
[TBL] [Abstract][Full Text] [Related]
9. Oncocytic Papillary Thyroid Carcinoma and Oncocytic Poorly Differentiated Thyroid Carcinoma: Clinical Features, Uptake, and Response to Radioactive Iodine Therapy, and Outcome.
Lukovic J; Petrovic I; Liu Z; Armstrong SM; Brierley JD; Tsang R; Pasternak JD; Gomez-Hernandez K; Liu A; Asa SL; Mete O
Front Endocrinol (Lausanne); 2021; 12():795184. PubMed ID: 34975765
[TBL] [Abstract][Full Text] [Related]
10. 30mCi radioactive iodine achieving comparative excellent response in intermediate/high-risk nonmetastatic papillary thyroid cancer: a propensity score matching study.
Zhang Y; Wang C; Zhang X; Li H; Li X; Lin Y
Endocrine; 2018 Dec; 62(3):655-662. PubMed ID: 30145748
[TBL] [Abstract][Full Text] [Related]
11. Noninferior response in BRAF(V600E) mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy.
Li J; Liang J; Zhao T; Lin Y
Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1034-9. PubMed ID: 26780618
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer.
Ruel E; Thomas S; Dinan M; Perkins JM; Roman SA; Sosa JA
J Clin Endocrinol Metab; 2015 Apr; 100(4):1529-36. PubMed ID: 25642591
[TBL] [Abstract][Full Text] [Related]
13. Association between excessive urinary iodine excretion and failure of radioactive iodine thyroid ablation in patients with papillary thyroid cancer.
Sohn SY; Choi JY; Jang HW; Kim HJ; Jin SM; Kim SW; Suh S; Hur KY; Kim JH; Chung JH; Kim SW
Thyroid; 2013 Jun; 23(6):741-7. PubMed ID: 23205883
[TBL] [Abstract][Full Text] [Related]
14. Associations between body mass index and clinico-pathological characteristics of papillary thyroid cancer.
Kim HJ; Kim NK; Choi JH; Sohn SY; Kim SW; Jin SM; Jang HW; Suh S; Min YK; Chung JH; Kim SW
Clin Endocrinol (Oxf); 2013 Jan; 78(1):134-40. PubMed ID: 22812676
[TBL] [Abstract][Full Text] [Related]
15. Radioactive iodine ablation may not decrease the risk of recurrence in intermediate-risk papillary thyroid carcinoma.
Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
Endocr Relat Cancer; 2016 May; 23(5):367-76. PubMed ID: 26917553
[TBL] [Abstract][Full Text] [Related]
16. Is body mass index relevant to prognosis of papillary thyroid carcinoma? A clinicopathological cohort study.
Chung YS; Lee JH; Lee YD
Surg Today; 2017 Apr; 47(4):506-512. PubMed ID: 27654453
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcome of patients with papillary thyroid carcinoma who have recurrence after initial radioactive iodine therapy.
Vassilopoulou-Sellin R; Schultz PN; Haynie TP
Cancer; 1996 Aug; 78(3):493-501. PubMed ID: 8697396
[TBL] [Abstract][Full Text] [Related]
18. Analysis of Delayed Surgery and Clinical Outcomes in Intermediate- and High-risk Papillary Thyroid Cancer.
Zhou H; Wu J; Shi L; Wang Y; Liu B
J Clin Endocrinol Metab; 2022 Nov; 107(12):3389-3397. PubMed ID: 36056633
[TBL] [Abstract][Full Text] [Related]
19. Association of Radioactive Iodine Administration After Reoperation With Outcomes Among Patients With Recurrent or Persistent Papillary Thyroid Cancer.
Hung ML; Wu JX; Li N; Livhits MJ; Yeh MW
JAMA Surg; 2018 Dec; 153(12):1098-1104. PubMed ID: 30140908
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Survival Outcomes Following Postsurgical Radioactive Iodine Versus External Beam Radiation in Stage IV Differentiated Thyroid Carcinoma.
Yang Z; Flores J; Katz S; Nathan CA; Mehta V
Thyroid; 2017 Jul; 27(7):944-952. PubMed ID: 28446057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
